Rockwell Medical, Inc. logo

Rockwell Medical, Inc.

RMTI

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

最新数据

US$8.01

+US$0.46 · +6.02%

8月21日 15:55 ET

RMTI公司概览

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

GoAI评分

Sell

Trim exposure — unfavorable risk-reward

估值

50

Fair Value

动量

17

Strong Down

情绪

59

Mixed

风险韧性

23

High Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考,并非投资建议。

公司概况

公司网站

Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.

行业
Drug Manufacturers - Specialty & Generic
部门
Healthcare
总部
US
首席执行官
Mark Strobeck
上市以来
1998年1月27日
雇员
157

市场位置

成交量
2.58万
0.77× 平均值
平均成交量
3.35万
日均成交量
市值
3197.09万 USD
贝塔
1.62
市场参考 1

财务数据

财务快照

最近十二个月

财务健康

奥特曼 Z 分数
-7.62
皮奥特罗斯基 F 分数
5 共 9 个

财报历史与展望

最新财年每股收益
-1.5
2025财年
最新财年收入
6925.8万 USD
2025财年 · 同比-31.76%

年度每股收益趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期
年度每股收益趋势3.55-11.67-26.88-42.1121财年22财年23财年24财年25财年

年度营收趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期
年度营收趋势1.05亿8962.16万7379.84万5797.52万21财年22财年23财年24财年25财年

分析师评级

第三方分析师预期可能变化,并非 GoAI 建议。

分析师目标价

平均目标

US$20.00

上涨空间 146.91%
过去 12 个月12个月预测

价格历史记录不可用

最高:US$20.00平均的:US$20.00最低:US$20.00

评级分布

16项评级
强力买入00%
买入1063%
持有213%
卖出425%
强力卖出00%

RMTI 消息

RMTI同业公司

持有RMTI的ETF

报告持有此股票敞口的交易所交易基金。

继续GoAI的研究

在 GoAI 中研究RMTI

research.disclaimer